Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications
M Chen, J Jiang, J Hou - Biomarker Research, 2023 - Springer
Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation
of plasma cells. Although therapeutic advances have been made to improve clinical …
of plasma cells. Although therapeutic advances have been made to improve clinical …
Hematopoietic stem cell aging and leukemia transformation
With aging, hematopoietic stem cells (HSCs) have an impaired ability to regenerate,
differentiate, and produce an entire repertoire of mature blood and immune cells. Owing to …
differentiate, and produce an entire repertoire of mature blood and immune cells. Owing to …
[HTML][HTML] The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities
E Ramberger, V Sapozhnikova, YLD Ng, A Dolnik… - Nature cancer, 2024 - nature.com
Multiple myeloma (MM) is a plasma cell malignancy of the bone marrow. Despite therapeutic
advances, MM remains incurable, and better risk stratification as well as new therapies are …
advances, MM remains incurable, and better risk stratification as well as new therapies are …
T-cell redirecting therapies in haematological malignancies: current developments and novel strategies for improved targeting
GSF Anderson, MA Chapman - Molecular Therapy, 2024 - cell.com
T-cell redirecting therapies (TCRTs), such as CAR-or TCR T-cells and T-cell engagers, have
emerged as a highly effective treatment modality, particularly in the B-and plasma cell …
emerged as a highly effective treatment modality, particularly in the B-and plasma cell …
Mapping the cancer surface proteome in search of target antigens for immunotherapy
Immune-based therapeutic interventions recognizing proteins localized on the cell surface of
cancer cells are emerging as a promising cancer treatment. Antibody-based therapies and …
cancer cells are emerging as a promising cancer treatment. Antibody-based therapies and …
Road testing new CAR design strategies in multiple myeloma
A deeper understanding of basic immunology principles and advances in bioengineering
have accelerated the mass production of genetically-reprogrammed T-cells as living drugs …
have accelerated the mass production of genetically-reprogrammed T-cells as living drugs …
Improvement of untargeted proteomics workflow for surfaceome profiling and its evaluation through the implementation of quality controls: Application to multiple …
Background Comprehensive surfaceome profiling of cancer cells using mass spectrometry
(MS)-based technologies is a valuable approach to identify new antigens that could be …
(MS)-based technologies is a valuable approach to identify new antigens that could be …
Design of a potential Sema4A-based multi-epitope vaccine to combat triple-negative breast cancer: An immunoinformatic approach
P Paranthaman, S Veerappapillai - Medical Oncology, 2023 - Springer
Immunotherapy is revamping the therapeutic strategies for TNBC owing to its higher
mutational burden and tumour-associated antigens. One of the most intriguing …
mutational burden and tumour-associated antigens. One of the most intriguing …
Semaphorins and the bone marrow microenvironment: New candidates that influence the hematopoietic system
CE da Silva Gonçalves, RA Fock - Cytokine & Growth Factor Reviews, 2024 - Elsevier
The bone marrow is a haven for hematopoietic and non-hematopoietic cells, creating
complex micro-anatomical regions called niches. These distinct niches all participate in an …
complex micro-anatomical regions called niches. These distinct niches all participate in an …
CAR T cell Toxicities: Bedside to Bench-How Novel Toxicities Inform Laboratory Investigations
Multiple chimeric antigen receptor (CAR) T cell therapies are FDA approved, and several
are under development. While effective for some cancers, toxicities remain a limitation. The …
are under development. While effective for some cancers, toxicities remain a limitation. The …